ATE205536T1 - Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe - Google Patents

Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe

Info

Publication number
ATE205536T1
ATE205536T1 AT93921524T AT93921524T ATE205536T1 AT E205536 T1 ATE205536 T1 AT E205536T1 AT 93921524 T AT93921524 T AT 93921524T AT 93921524 T AT93921524 T AT 93921524T AT E205536 T1 ATE205536 T1 AT E205536T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
mutants
hav
vaccines
Prior art date
Application number
AT93921524T
Other languages
English (en)
Inventor
Ann W Funkhouser
Suzanne U Emerson
Robert H Purcell
Hondt Eric D
Original Assignee
Smithkline Beecham Biolog
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25485989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE205536(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog, Us Health filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of ATE205536T1 publication Critical patent/ATE205536T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT93921524T 1992-09-18 1993-09-17 Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe ATE205536T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94733892A 1992-09-18 1992-09-18
PCT/US1993/008610 WO1994006446A1 (en) 1992-09-18 1993-09-17 Hepatitis a virus vaccines

Publications (1)

Publication Number Publication Date
ATE205536T1 true ATE205536T1 (de) 2001-09-15

Family

ID=25485989

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921524T ATE205536T1 (de) 1992-09-18 1993-09-17 Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe

Country Status (13)

Country Link
US (4) US6180110B1 (de)
EP (1) EP0666751B1 (de)
JP (1) JP3523646B2 (de)
AT (1) ATE205536T1 (de)
AU (1) AU687012B2 (de)
CA (1) CA2144317C (de)
DE (1) DE69330758T2 (de)
DK (1) DK0666751T3 (de)
ES (1) ES2164074T3 (de)
NZ (1) NZ256278A (de)
PT (1) PT666751E (de)
SG (1) SG73999A1 (de)
WO (1) WO1994006446A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
JP4753943B2 (ja) * 2004-07-13 2011-08-24 ジェン−プローブ・インコーポレーテッド Ａ型肝炎ウイルス核酸の検出のための組成物及び方法
US20100055670A1 (en) * 2005-06-28 2010-03-04 The Government of the US, Represented by the Secretary, Dept. of Health and Human Services Growth of wild-type hepatitis a virus in cell culture
US7831574B2 (en) * 2006-05-12 2010-11-09 Oracle International Corporation Apparatus and method for forming a homogenous transaction data store from heterogeneous sources
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN102174477B (zh) * 2010-12-28 2012-11-21 深圳康泰生物制品股份有限公司 甲型肝炎病毒株sh及其二倍体细胞适应方法
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika
KR102277089B1 (ko) 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스
WO2025022020A1 (en) * 2023-07-27 2025-01-30 Universitat De Barcelona Vaccine composition for the treatment or prevention of hepatitis a infection

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US5516630A (en) 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
GB8800100D0 (en) * 1988-01-05 1988-02-10 Almond J W Attenuated viruses
DE542949T1 (de) 1991-05-08 1993-09-02 Schweiz. Serum- & Impfinstitut Bern, Bern Hepatitis a virusstamm, verfahren zur isolierung eines hepatitis a virusstammes und vakzine hepatitis a.

Also Published As

Publication number Publication date
JP3523646B2 (ja) 2004-04-26
HK1013667A1 (en) 1999-09-03
AU687012B2 (en) 1998-02-19
WO1994006446A1 (en) 1994-03-31
DE69330758D1 (de) 2001-10-18
EP0666751A4 (de) 1996-04-24
SG73999A1 (en) 2000-07-18
US6680060B2 (en) 2004-01-20
US6113912A (en) 2000-09-05
CA2144317A1 (en) 1994-03-31
ES2164074T3 (es) 2002-02-16
AU4858593A (en) 1994-04-12
EP0666751B1 (de) 2001-09-12
DE69330758T2 (de) 2002-07-04
JPH08504094A (ja) 1996-05-07
US6180110B1 (en) 2001-01-30
EP0666751A1 (de) 1995-08-16
NZ256278A (en) 1996-11-26
CA2144317C (en) 2004-08-03
PT666751E (pt) 2002-01-30
US20020176869A1 (en) 2002-11-28
DK0666751T3 (da) 2001-11-12
US6423318B1 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
ATE205536T1 (de) Mutanten von hepatitis a virus stamm hm-175 zur verwendung als hepatitis a virus impfstoffe
FI953731A0 (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
ATE127694T1 (de) Lebende impfstoffe.
NZ226332A (en) Vaccine comprising transmissible gastroenteritis virus of swine for preventing canine coronavirus infection in dogs and process for preparation thereof
AU7763294A (en) Live in ovo vaccine
ATE70561T1 (de) Verfahren zur kultur des virus der rhinotracheitis des truthahnes und daraus hergestelltes vakzin.
SE9003198L (sv) Fiskvaccin omfattande en virulent, invasiv bakterie
NO950483L (no) Vaksine mot hepatitt-A
US4400472A (en) Novel rabies virus strain and a process for its preparation
DE69824856D1 (de) Rückgewinnung von viren aus zellkulturen durch verwendung einer hypertonischen salzlösung
NO872919D0 (no) Fremstilling av pertussis-toksin ved dyrkning av bodella pertussis.
DE69633233D1 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
US3769415A (en) Method of preparing a killed vaccine for oral use
FI98377B (fi) Adherentisti sitoutuneita soluja sisältävä matriisi ja menetelmä virus/virusantigeenin tuottamiseksi
Gresikova et al. Characteristics of some tick-borne encephalitis virus strains isolated in Slovakia
RU2054038C1 (ru) Штамм вируса инфекционной бурсальной болезни птиц
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
Sen et al. Development of an effective vaccine against foot-and-mouth disease with partially purified and concentrated virus antigen
Nishibe et al. Induction of SMON-type virus from avian infectious laryngotracheitis virus
RU96115433A (ru) Вакцинный штамм вируса кори л-16в, способ его культивирования и живая вакцина для профилактики кори
Khodzhaev A study of the postvaccination immunity of guinea pigs repeatedly inoculated with a strain of brucella melitensis: Communication II
Zhidkova BIOLOGICAL PROPERTIES OF THE A22 VARIANT OF HOOF AND MOUTH DISEASE VIRUS
RU94030087A (ru) Способ получения вакцины против болезни гамборо
BG61384B1 (bg) метод за получаване на жива атенуирана клетъчно-културална ваксина против псевдочума по птиците
NO931821L (no) Hepatitt b vaksinepreparat som omfatter et gallesyresalt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution